E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetes, type 2 |
Diabetes, type 2 |
|
E.1.1.1 | Medical condition in easily understood language |
Diabetes, type 2 |
Sukkersyge, type 2 |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Physiological processes [G07] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 100000072461 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Empagliflozin is a sodium–glucose cotransporter 2 (SGLT-2) inhibitor, and is used in treatment of diabetes type 2. It is previously shown that SGLT-2 inhibitors have a remarkable protective effect on the heart by reducing death caused by cardiac diseases with 38%. The reasons for these effects are still unknown, but it is known that SGLT-2 treatment increase ketogenesis. We have in a previous study found that ketone body infusion shifts cardiac metabolism towards ketone body oxidation, which possibly increases cardiac efficiency. It is also shown that SGLT-2 inhibitors have reno protective effects. The aim of this study is to examine the effects of SGLT-2 treatment by: - Examination of substrate metabolism in heart and kidney measured by PET. - Examination of perfusion and total energy consumption in the heart and kidney measured by PET. - Indirect calorimetry, bloodsamples, fat- and muscle biopsies, DXA-scan, measurement of arterial stiffness and oral glucose tolerance test. |
Empagliflozin er en såkaldt sodium–glucose cotransporter 2 (SGLT-2) hæmmer, og bruges til behandling af type 2 sukkersyge. Det har vist sig, at SGLT-2 hæmmere har en bemærkelsesværdig beskyttende effekt på hjertet, ved at reducere død pga. hjertesygdom med 38%. Baggrunden herfor er endnu ikke belyst, men det er vist, at behandlingen øger ketonstofdannelse. Vi har i et tidligere studie fundet, at infusion af ketonstof skifter hjertets forbrænding over mod ketonstofforbrænding, hvilket potentielt forbedrer hjertets energiudnyttelse. Det er også vist, at SGLT-2 hæmmerne har en betydelig nyrebeskyttende effekt. Formålet med dette forsøg er således at undersøge SGLT-2 hæmmeres beskyttende effekt på hjertet og nyrerne ved: - Undersøgelse af substrat metabolisme i hjerte og nyrer med PET. - Undersøgelse af perfusion og totalt energiforbrug i hjertet og nyrerne målt med PET. - Indirekte kaloeriemetri, fedt- og muskelbiopsi, blodprøver, DXA, arteriel stivhed og oral glukose tolerance test. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Ikke angivet |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age: 50-70 years • Type 2 diabetes for > 1 år • HbA1c: 53-75 mmol/mol • Metformin treatment as only anti diabetic medicin
|
• Alder: 50-70 år • Konstateret type 2 diabetes gennem >1 år • HbA1c: 53-75 mmol/mol • Metforminbehandling som eneste medicinske antidiabetiske behandling
|
|
E.4 | Principal exclusion criteria |
• Diabetes for less than 1 year • Changes in any kind of medicine through the last one month before beginning of the study. • Recent acute myocardial infarction (< 1 year) , liver disease (ALAT > x 3 of upper normal range), kidney failure (eGFR<60 ml/min), current or previous cancer disease, anaemia (Hb < 6,5) • Previous ketoacidosis • Several genital infections (bacterial/fungal infections) • Blooddonation the last 3 months before beginning of the study • Participation in examinations with radioactive isotopes during the last 6 months before beginning of the study • Current alcohol abuse (more than 21 units per week)
|
• Nykonstateret diabetes (inden for et 1 år) • Ændring af alt medicin en måned op til forsøgsstart. • Akut myokardieinfarkt inden for det sidste år, leversygdom (ALAT > x 3 af øvre normalområde), nyresvigt (eGFR<60 ml/min), aktuel eller tidligere malign sygdom, Anæmi (Hb < 6,5) • Tidligere ketoacidose • Gentagne underlivsinfektioner (bakterier/svampe) • Bloddonation indenfor de sidste 3 måneder inden undersøgelsen • Deltagelse i forsøg/undersøgelser involverende radioaktive isotoper indenfor de seneste 6 måneder • Aktuelt alkoholmisbrug (over 21 genstande om ugen)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Cardiac and renal: - Free fatty acids uptake, oxidation and re-esterification - Glucose uptake - Oxygen consumption and energy efficiency - Perfusion |
Hjerte og nyrer: - Frie fedtsyrer optag, forbrænding og reesterificering - Glukose optag - Ilt forbrug og energiudnyttelse - Perfusion
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 4 weeks treatment with - placebo - Empagliflozin |
Efter 4 ugers behandling med - placebo - Empagliflozin |
|
E.5.2 | Secondary end point(s) |
- Body composition (DXA) - Energy expenditure (Indirect calorimetry) - Insulin sensitivity and secretion (Oral glucose tolerance test) - Intracelular signalling in muscle and adipose tissue - Arterial stiffness
|
- Krops sammensætning (DXA) - Energiforbrug (Indirekte kaloriemetri) - Insulin følsomhed og sekretion (Oral glukose tolerance test) - Intracellulær signallering i muskel- og fedtvæv - Arteriel karstivhed |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 4 weeks treatment with - placebo - Empagliflozin |
Efter 4 ugers behandling med - placebo - Empagliflozin |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
Sidste besøg af sidste deltager |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |